The Effect Of Upper Gastrointestinal Hemorrhage Induced By Dual Anti-platelet Treatment In PCI Patient

ObjectiveTo investigate the clinical characters and the risk factors of dual anti-platelet treatment related upper gastrointestinal hemorrhage.Methods1. A retrospective review of the records of484admissions for patients with Gastrointestinal Bleeding (GIB). According if use the anti-platelets, group B composed of172patients using any anti-platelets, and group A312patients not using any such drugs. The clinical outcomes and endoscopic findings were compared.2.2004patients taking dual anti-platelet treatment for coronary heart disease were reviewed cilinical characteristics, including sex, age, BMI, smoking, drinking, history of digestive disease, history of hypertension, diabetes, cerebrovascular disease, time of dual anti-platelet therapy, use of PPI, laboratory abnormalities, and so on. Compare the different characteristics of gastrointestinal bleeding, then analyse the risk factors of upper gastrointestinal bleeding.Results1. Patients in Group B were older than patients in group A (68.42±9.62vs56.54±16.80, P<0.05).In Group B, more patients with hypertension, coronary heart disease, diabete, more patients have gastric ulcers in the bottom or body of stomach and less gastrointestinal symptoms in Group B, differences with significant (P<0.05).2.The incidence of dual anti-platelet treatment related upper gastrointestinal bleeding was associated with age,history of smoke, obesity, history of digestive disease, history of hypertension, abnormal test parameters and the use of PPI. Age, history of smoking, history of hypertension, abnormal PLT, abnormal Cr, abnormal Hb is risk factors for upper gastrointestinal hemorrhage induced by anti-platelet drugs, and application of PPI is protective factor.Conclusion The patients of upper gastrointestinal hemorrhage induced by anti-platelet drugs increase every year. Ages, history of hypertension, history of coronary heart disease, history of diabetes are important influencing factors. Gastric ulcers in the bottom or body of stomach and less gastrointestinal symptoms are clinical characteristics. Age, history of smoking, history of hypertension, abnormal PLT, abnormal Cr, abnormal Hb is risk factors for upper gastrointestinal hemorrhage induced by anti-platelet drugs, and application of PPI is protective factor. Strengthen cognition of upper gastrointestinal bleeding induced by dual anti-platelet treatment, and take appropriate measures to reduce the incidence of gastrointestinal bleeding in PCI patients.